Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart safety check for new myelofibrosis drug in healthy volunteers

NCT ID NCT07708272

Not yet recruiting Knowledge-focused Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study evaluates whether a single dose of TQ05105, a JAK inhibitor being developed for myelofibrosis, affects the heart's electrical activity (QT interval) in healthy Chinese adults. Sixty participants receive TQ05105, placebo, and moxifloxacin (a positive control) in a crossover design. The main goal is to see if TQ05105 causes any heart rhythm changes, which is a key safety step before larger patient trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TQ05105 tablets, a Janus kinase (JAK) inhibitor
What this could lead to
If this trial shows TQ05105 does not affect heart rhythm, it could support further development of this drug for myelofibrosis with a known cardiac safety profile.
What could go wrong
This is an early-phase study in healthy people, not patients. The drug may still cause heart issues in patients or fail in later trials for other reasons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • PKU Care Luzhong Hospital

    Zibo, Shandong, 255499, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.